Medtronic at ESC: Encouraging Results From TAVR And Arrhythmia Genetics Studies, But Disappointment For HF Monitoring
This article was originally published in Clinica
Executive Summary
Results from three major trials sponsored by Medtronic made news at the 2015 ESC Congress in London, including more positive “real world” results with the CoreValve transcatheter aortic valve replacement system, evidence linking specific genes to abnormal heart rhythms, and disappointing results from a trial of heart failure management with Medtronic’s Optivol fluid status monitoring used in conjunction with Carelink remote cardiac rhythm management monitoring network.